PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--
Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 15/237,364, relating to “miRNA Expression Signature in the Classification of Thyroid Tumors.” The allowed patent claims a method of classifying a thyroid lesion sample obtained by fine needle aspiration as malignant or benign, through a classifier algorithm that utilizes the expression profile of microRNAs detected by real time polymerase chain reaction (RT-PCR).
“We continue to fortify our patent portfolio around the Reveal assay, further protecting and distinguishing it from would-be competitors and firmly establishing Rosetta’s leading intellectual property position in microRNA diagnostics,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
“Our core commercial strategy continues to focus on growing Reveal utilization for the classification of indeterminate thyroid cases, where many patients with indeterminate results undergo surgery as a precaution despite the fact that up to 80% of these cases are benign. This exposes patients to unnecessary surgical risk and costs the healthcare system hundreds of millions of dollars. We believe due to our proprietary classifier algorithm and microRNA signature, we can help prevent up to 75% of unnecessary thyroid surgeries and has the potential to save healthcare payers an average of approximately $6,000 per patient tested with Reveal. This new patent is central to protecting Reveal,” added Mr. Berlin.
Rosetta Genomics maintains a robust intellectual property strategy to protect its leadership position in microRNA technology and now has 64 patents granted and 33 patents pending worldwide.
About Rosetta Genomics
Rosetta is pioneering the field of
molecular diagnostics by offering rapid and accurate diagnostic
information that enables physicians to make timelier and more informed
treatment decisions to improve patient care. Rosetta has developed a
portfolio of unique diagnostic solutions for oncologists, urologists,
endocrinologists, cytopathologists and other specialists to help them
deliver better care to their patients. RosettaGX Reveal™, a Thyroid
microRNA Classifier for the diagnosis of cancer in thyroid nodules, as
well as the full RosettaGX™ portfolio of cancer testing services are
commercially available through the Company’s Philadelphia, PA- and Lake
Forest, CA-based CAP-accredited, CLIA-certified labs.
Forward-Looking Statement Disclaimer
Various statements in
this release, including but not limited to, statements relating to
increasing Reveal utilization, saving healthcare payers on average
$6,000 per patient, and preventing up to 75% of unnecessary surgeries
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section
of Rosetta’s most recently filed Annual Report on Form 20-F, as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not be
relied upon as representing its views as of any subsequent date. Rosetta
does not assume any obligation to update any forward-looking statements
unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005517/en/
